ERBB2 and breast carcinoma: Another neoadjuvant trial that addressed the deletion of anthracyclines was the TRAIN-2 study, which randomly assigned patients with stage II or III HER2-positive breast cancer to NAC with or without anthracyclines in the presence of dual HER2 blockade with trastuzumab and pertuzumab70.